We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory eect on Cyr61 gene expression. Lastly, retinoic acid has a negative eect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these eects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no signi®cant eect on cells that express high levels of Cyr61. Our ®ndings suggest an association between increased Cyr61 expression and an aggressive phenotype of breast cancer cells. Oncogene (2002) 21, 964 ± 973.
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We have previously identi®ed an angiogenic regulator, Cyr61, as a protein potentially involved in breast cancer progression (Tsai et al., 2000) . Cyr61 belongs to the CCN family, which consists of Cyr61, CTFG, Nov, WISP-1, WISP-2, and WISP-3 . These structurally conserved proteins share four modular domains with similar sequence homologies . Cyr61 is a cysteine-rich, heparinbinding protein that is secreted and associated with the cell surface and the extracellular matrix (ECM) (Yang and Lau, 1991; Kirreva et al., 1997) . Cyr61 mediates cell adhesion, induces cellular migration, enhances growth factor-induced DNA synthesis in ®broblasts and endothelial cells, stimulates chemotaxis of ®bro-blasts and endothelial cells, and increases chondrogenesis in mesenchymal cells (O'Brien and Lau, 1992; Kireeva et al., 1996 Kireeva et al., , 1997 Kireeva et al., , 1998 Frazier et al., 1996; Wong et al., 1997; Kolesnikova and Lau, 1998; Babic et al., 1998) , possibly through its binding to integrin receptors, such as avb3, avb5, aIIbb3, and a6b1 Jedsadayanmata et al., 1999; Chen et al., 2000; Grzeszkiewicz et al., 2001) . Most signi®cantly, expression of Cyr61 enhances neovascularization and tumor formation of human tumor cells in immunode®cient mice (Babic et al., 1998 (Babic et al., , 1999 Xie et al., 2001) .
We have shown that Cyr61 is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies (Tsai et al., 2000) . In addition, we demonstrated that Cyr61 function is necessary for heregulin (HRG)-mediated chemomigration of breast cancer cells (Tsai et al., 2000) . We further determined that Cyr61 is sucient to promote breast cancer cells to bypass their normal estrogen requirement for growth, to induce progression of breast cancer cells to more aggressive and invasive phentoypes in vitro, and to induce tumor formation in vivo (Tsai et al., 2001, manuscript submitted) . To understand better the mechanism of Cyr61 action in promoting breast cancer progression, it is important to investigate how Cyr61 expression is regulated in breast cancer cells.
It is well known that Cyr61, an immediate-early gene, is transcriptionally activated by serum, plateletderived growth factor (PDGF), transforming growth factor-b1 (TGF-b1), and basic ®broblast growth factor (bFGF) in ®broblasts and neuronal cells (Lau and Nathans, 1987; O'Brien et al., 1992; Ryseck et al., 1991; Bunner et al., 1991) . Other cytokines, such as tumor necrosis factor a (TNFa) and interleukin-1 (IL-1) also strongly elevate the expression of Cyr61 (Scheutze et al., 1998) . Cyr61 is dierentially expressed by muscarinic acetylcholine receptors (mAChRs) in the brain (Albrecht et al., 2000) , and by factor VIIa and thrombin in human ®broblasts (Pendurthi et al., 2000) . Phorbol ester 12-O-tetradecanoyphorbol-13-acetate (TPA) mediates Cyr61 expression in the liver (Nathans et al., 1988) . Incidentally, others and we have found expression of Cyr61 involving protein kinase C (PKC) and the MEK/MAPK pathways (Chung and Ahn, 1998; Inuzuka et al., 1999; Albrecht et al., 2000; Tsai et al., 2001, manuscript submitted) . Cyr61 is also vitamin D-responsive in human osteoblasts and osteosarcoma cell lines (Scheutze et al., 1998) . Induction of Cyr61 may be attenuated by glucocorticoids in murine ®broblasts (Smith and Herschman, 1995) . Moreover, previous studies showed that murine Cyr61 is inducible by estrogen (E2) and tamoxifen (Tam) in the uterus of ovariectomized rats (Rivera-Gonzalez et al., 1998) . However, it is not clear how Cyr61 is regulated in human breast cancer, except it has been indicated that Cyr61 is E2-inducible, and that Tam inhibited its expression in human breast cancer cells (Xie et al., 2001) .
We have recently shown that Cyr61 is expressed in breast cancer cells, and that enhanced expression of Cyr61 correlates with lack of ER expression and with advanced breast cancer diseases (Tsai et al., 2000) . Here we investigate in more detail how Cyr61 expression is regulated in both ER-positive and ERnegative breast cancer cells. To determine whether Cyr61 expression was regulated by estrogen, antiestrogens (anti-E2), or both, in breast cancer cells that express or do not express ER, the levels of Cyr61 mRNA were measured in a time-dependent manner by RNase protection assays. Cells were grown in phenol red-free media containing FBS depleted of estrogenic compounds by charcoal adsorption, and treated in the presence or absence of E2.
As shown in Figure 1a , the mRNA levels of Cyr61 in MCF-7 cells under the condition of estrogen depletion was very low or nearly undetectable. In contrast, E2 markedly increased the expression of Cyr61 mRNA. Upregulation of Cyr61 was observed as early as 3 h after E2 treatment, as a 6-to 10-fold increase ( Figure  1a , top panel). The Cyr61 transcript, although slightly reduced after 9 h of treatment, was sustained for up to 72 h without signi®cant decreases (data not shown).
To provide a better understanding of the possible mechanism of anti-estrogenic eects, two distinct antiestrogens, Tam and ICI 182, 780 (ICI), were used. Tam functions as an antagonist as well as a partial agonist by binding to the ligand-binding domain, thus blocking transactivation of the AF-2 domain but not the AF-1 of the ER. ICI, a pure anti-estrogen, displays solely antagonistic eects by binding to the ER, disrupting (a,c,d) , total RNA was isolated at 0, 3, 6 and 9 h after treatments with E2 (1 nM), Tam (100 nM), ICI (100 nM), the combination of E2 and Tam, and the recombinant of E2 and ICI. The RNA was analysed for Cyr61 expression by the RNase protection assay as described previously (Tsai et al., 2000) . For (b), conditioned media was collected after 24 h of E2, Tam or ICI treatment and concentrated 506. Western blot analysis was then performed using 20 ml of the concentrated media. (e) MCF-7 cells were cultured in E2-depleted media and incubated with a control vehicle, and with E2 (1 mM) in the presence or absence of actinomycin D (Act-D; 100 nM) or cycloheximide (CHX; 0.05, 0.5, 1, and 10 mg/ml) for 6 h. Total RNA was isolated and analysed by the RNase protection assays as above. GAPDH is used as a control of RNA loading. Data were quanti®ed by densitometry and normalized to the level of GAPDH. Similar results were obtained from at least four independent experiments Figure 2 Eect of TPA on Cyr61 mRNA expression in breast cancer cells. (a) MCF-7 cells were treated with TPA (50, 100, 250, and 500 ng/ml) for 0, 0.5, 1, 2, and 3 h. Total RNA was isolated and analysed by the RNase protection assay. (b) MDA-MB-231 cells were treated with 50 ng/ml TPA for 0, 1, 2, 3, 6, and 24 h. Total RNA was isolated and analysed as described above. Data were quanti®ed by densitometry and normalized to the level of GAPDH. Similar results were obtained from at least three independent experiments the nuclear translocation of the ER, and inducing rapid degradation of the ER (MacGregor and Jordan, 1988) . We examined the eects of the anti-estrogens on E2 induction of Cyr61 expression. Cells were treated with E2 alone, or with the combination of E2 and anti-E2. Both anti-estrogens exerted antagonistic eects on E2.
Interestingly, treatment with either anti-estrogen on MCF-7 cells caused a marked upregulation of Cyr61 mRNA ( Figure 1a, top panel) . Tam induced the expression of Cyr61 mRNA by a sixfold increase after 3 h of treatment, and then its expression was reduced to the basal level after 9 h. On the other hand, ICI, a pure E2 antagonist, induced rapid Cyr61 upregulation kinetics ( Figure 1a , top panel), similar to that observed for E2; that is, the accumulated Cyr61 mRNA was seen as early as 3 h after treatment and maintained for up to 72 h (data not shown). Interestingly, the combination of E2 with Tam or ICI abrogated the expression of Cyr61. This eect can be due to a change in receptor occupancy and the modi®cation of the ER pockets that each of these compounds interfere with. Quanti®cation of Cyr61 protein expression was performed using densitometry ( Figure 1a, bottom panel) .
Moreover, we demonstrated that Cyr61 protein expression was also upregulated (over 10 ± 20-fold) by E2, Tam and ICI in MCF-7 cells (Figure 1b) . Quanti®cation of the Cyr61 expression was performed using densitometry. These cells were grown in phenol red-free media containing FBS depleted of estrogenic compounds by charcoal adsorption for 4 days and treated with 10 79 M E2 for 24 h. The media was then collected and concentrated 50 times. Western blot analysis was performed as previously described (Tsai et al., 2000) . While writing this manuscript, these data were con®rmed recently by Sampath et al., 2001 .
We then examined the expression of Cyr61 in E2-independent and anti-E2-resistant breast cancer cells, such as HRG-transfected MCF-7 clones (MCF-7/ HRG) (Tang et al., 1996) and MDA-MB-231. We ®rst determined whether E2-induced Cyr61 expression is mediated in one of the MCF-7/HRG clones (clone T6), all of which express high levels of HRG and moderate levels of Cyr61. Both E2 and anti-E2 transiently induced Cyr61 expression in MCF-7/HRG cells. The highest expression was observed after 3 h of E2 treatment, returning to the basal level shortly after 9 h of treatment. Although the MCF-7/HRG cells acquired an E2-independent phenotype both in vitro and in vivo (Tang et al., 1996) , it appears that these cells respond slightly to E2 in regulating Cyr61 , 10, 20, 30, 45, 60, 120, 180 , and 240 min. Total RNA was isolated and analysed for Cyr61 mRNA levels by the RNase protection assays. Data were quanti®ed by densitometry and normalized to the level of GAPDH. Similar results were obtained from at least three independent experiments expression, however with dierent kinetics as compared to wild-type MCF-7 cells (Figure 1c) . Furthermore, the level of Cyr61 induction by E2 and anti-E2 in the MCF-7/HRg cells was 2 ± 3-fold lower as compared to wild-type MCF-7 cells. Moreover, while ICI blocked E2-mediated Cyr61 expression by 50 to 70% as early as 3 h after treatment, Tam showed an apparent delayed blockage of 50% after 6 h of treatment and a complete blockage after 9 h of treatment ( Figure 1c) . Thus, the eects of Tam and ICI on E2 induction of Cyr61 expression appear to result from distinct pathways in MCF-7/HRG cells, possibly because these cells become resistant to both Tam and ICI, while only Tam has agonistic eect and induces tumor growth in vivo (Atlas et al., 2001, manuscript submitted). Quanti®ca-tion of the Cyr61 expression is shown in the bottom panel of Figure 1c using densitometry.
Next we examined the eect of E2 on Cyr61 expression in breast cancer cells that do not express ER. As expected and shown in Figure 1d , E2 and anti-E2 no longer mediate the expression of Cyr61 in MDA-MB-231 cells, which express high levels of endogenous Cyr61. This ®nding is consistent with the phenotypes of MDA-MB-231, which is ER-negative, E2-independent, anti-E2-resistant, highly invasive, and metastatic in vivo. Quanti®cation of the Cyr61 expression was performed using densitometry and is shown in Figure 1d , bottom panel.
Together, our results indicate that the fold induction of Cyr61 by E2 and or anti-E2 coincides with the endogenous levels of Cyr61 expression and is inversely correlated with the levels of ER expression in breast cancer cells as shown in Figure 1a ,c,d. Here we demonstrate that E2, a tumor-promoting hormone, highly induces the expression of Cyr61 in breast cancer cells that express ER. In cells that acquire E2-independence but still express ER, such as the MCF-7/HRG cells, E2 induces Cyr61 to a much lower extent. In contrast, in cells that are very aggressive, do not express ER, and express high levels of Cyr61, E2 fails to further induce Cyr61 expression. These results are consistent with the hypothesis that Cyr61 expression correlates with the aggressiveness of the breast tumors, which in turn correlates with the lack of ER expression (Tsai et al., 2000) .
Our data clearly demonstrate that Cyr61 is an E2-inducible gene in breast cancer cells. To investigate further whether transcription is involved in the E2-mediated increase in Cyr61 mRNA steady-state levels, MCF-7 cells were depleted of E2-like compounds and incubated with E2 (1 nM) and actinomycin-D (100 nM), which is an RNA synthesis inhibitor. As shown in Figure 1e , we demonstrate that E2 stimulates Cyr61 expression in MCF-7 cells (Figure 1e) , and that actinomycin-D treatment (100 mM) has no eect on E2-mediated Cyr61 expression, indicating that de novo RNA synthesis is not required in E2 induction of Cyr61. The fact that actinomycin-D upregulates the mRNA levels suggests that although the de novo RNA synthesis is inhibited there is upregulation of Cyr61. If so, de novo of Cyr61-mRNA cannot account for that. It is therefore possible that the upregulation is due to the increased stability of the RNA, and the inability of protein(s) that may be involved in the recycling of the mRNA in question are not transcribed. This is supported by the fact that when protein synthesis is inhibited there is also upregulation of mRNA, supporting the same possible mechanism, or in the later case the relief of repression. It is also possible that E2 increases the stability of the mRNA. We then determined whether de novo protein synthesis is necessary for the induction of Cyr61 by E2. MCF-7 cells were depleted of E2-like compounds prior to the treatment with E2 in the presence or absence of a protein synthesis inhibitor, cycloheximide. As shown in Figure 1e , the stimulatory eect of E2 was not blocked by cycloheximide. Interestingly, cycloheximide treatments markedly increased the basal level of Cyr61 expression and further increased E2-induced Cyr61 mRNA accumulation by 6 ± 7-fold in a dose-dependent manner. These results indicate that a rapid accumulation of Cyr61 mRNA involved a labile protein(s), and that cycloheximide prevented the de novo protein synthesis of a negative regulator of Cyr61. Our results are consistent with the data by Sampath et al., 2001 that cycloheximide does not block E2-regulated Cyr61 expression. However, we showed that cycloheximide alone regulated Cyr61 expression. In addition, our results clearly demonstrate the increase in Cyr61 expression in the presence of cycloheximide at three dierent concentrations in the presence or absence of physiological concentration of E2 (1 nM), whereas their data have only one concentration of cycloheximide and a 10 times higher concentration of E2 (10 nM). The discrepancy between our ®ndings and Sampath et al. (2001) could be due to the known clonogenicity of MCF-7 cells. In addition, studies with actinomycin-D or cycloheximide alone were not provided in the abovecited publication. We have followed up the E2 eect on Cyr61 expression, and the Cyr61 mRNA level was sustained up to 72 h without signi®cant decrease.
It is known that nuclear steroid/thyroid/retinoid receptors and c-erbB membrane receptor tyrosine kinases control epithelial cell growth and dierentiation. Retinoic acid receptor (RAR) can dimerize with the vitamin D receptor (VDR), the glucocorticoid receptor, or the thyroid receptor (Schneider et al., 1999) . Molecular interactions between RARs and cerbB2, ER and c-erbB2, and between ER and RARa have been reported (Flicker et al., 1997; Schneider et al., 1999) . Moreover, these nuclear receptors and protein kinase signaling, such as protein kinase A (PKA) and protein kinase C (PKC), communicate with each other, perhaps via cross-talk regulatory factors (Schneider et al., 1999) . It is well documented that retinoid signaling via retinoic acid (RA) and retinoid X receptors (RARs and RXRs) regulates mammary epithelial cell growth, dierentiation, morphogenesis, and apoptosis (Glass et al., 1997) . Therefore, we next investigated whether TPA, vitamin D, and retinoic acid (RA) play any role in the regulation of Cyr61 expression in breast cancer cells.
TPA is an eective regulator of growth of many dierent cell types. It activates PKC, which plays a key role in the control of many signaling pathways involved in growth, dierentiation, and cellular transformation. Previous studies have shown that Cyr61 is induced by phorbol ester TPA in ®broblasts (Nathans et al., 1988) . It has been suggested that Cyr61 may involve PKC pathways in preadipocyte cells (Inuzuka et al., 1999) . Since activation of the PKC pathways has been shown to be a possible mechanism in the acquisition of drug resistance and of aggressive behavior in breast cancer cells (Bowden et al., 1999) , we tested the eects of TPA on the expression of Cyr61 in breast cancer cells. As shown in Figure 2a , TPA induces upregulation of Cyr61 expression (mRNA) in MCF-7 cells in a time-dependent manner, in any dose used (from 50 ng/ml to 500 ng/ml). Cyr61 transcripts were seen to increase rapidly after 30 min of treatment with TPA, reached the peak level after 2 h of treatment (a 15-fold increase), and were maintained at that high level longer than 24 h (data not shown). Interestingly, TPA induced the expression of Cyr61 expression in MDA-MB-231 cells by about 1.5-fold and this is sustained up to 24 h (Figure 2b ). These results indicate that activation of the PKC pathways may be involved in the upregulation of Cyr61, resulting in the progression of breast cancer cells.
The active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (1, 2D3 and its several analogues are novel putative anticancer agents, with their ability to induce growth inhibition, dierentiation, and apoptosis in tumor cells. 1,25-OH) 2D3 binds to the nuclear VDR with high anity and elicits its action regulating gene expression in target cells by binding to vitamin D-responsive elements (Haussler et al., 1995) . Cyr61 mRNA steady-state levels have been shown to be stimulated by 1,25-(OH) 2D3 in osteoblasts (Scheutze et al., 1998) . Moreover, a close correlation between VDR abundance and cell proliferation rate has been shown in MCF-7 breast cancer cells, HL-60 myeloblastic cells, and several leukemia cell lines (Folgueira et al., 2000) . Thus, we investigated whether Cyr61 expression in breast cancer cells could also be mediated by 1,25-(OH) 2D3 . As shown in Figure 3a , 1,25-(OH) 2D3 exerts rapid and transient induction of Cyr61 steadystate mRNA levels in MCF-7 cells. In these cells, Cyr61 expression was upregulated by 1,25-(OH) 2D3 after 1 h of treatment, an eect that rapidly declined to basal levels after 2 h of treatment. By contrast, 1,25-(OH) 2D3 has no eect on Cyr61 expression in MDA-MD-231 cells (Figure 3b ). It is possible that the level of the VDR is dierent between ER-positive and ERnegative breast cancer cells (Agadir et al., 1999; Escaleira and Brentani, 1999) . More likely, the extent of transcriptional co-activators and/or co-repressors, and the ligand availability of heterologous steroid hormone receptors, such as RAR and RXR, may determine the diverse function of VDR in breast cancer cells. In addition, 1,25-(OH) 2D3 has been shown to downregulate ER in MCF-7 cells (Nolan et al., 1998) (Figure 3b) , it is conceivable that Cry61 plays little or no role, in the development of Vitamin D resistance. Since all trans-retinoic acid is a potent regulator of growth of cancer cells, and RA exerts a growth inhibitory eect on ER-positive but not on ER-negative breast cancer cells (Sheikh et al., 1994; Srivastava et al., 1999) , and since Cyr61-overexpressing breast cancer cells acquire a growth advantage, we studied whether Cyr61 was an RAtargeted gene in MCF-7 cells. MCF-7 cells were treated with tRA in a time-and dose-dependent manner. Interestingly, Cyr61 expression was rapidly downregulated by RA in MCF-7 cells. This inhibitory eect was evident at 2 h, at which time Cyr61 expression was decreased to 40 ± 45%, as compared to the control (Figure 4a ). On the other hand, RA has no eect on the Cyr61 level in MDA-MB-231 cells (Figure 4b ). These results are consistent with the notion that RA exerts growth-inhibitory eects on breast cancer cells by ER-mediated enhancement of RAR levels, and possibly via an ER-dependent downregulation of growth-promoting factor(s).
In summary, we have demonstrated that Cyr61 is regulated by E2, and that anti-estrogens can block this induction in MCF-7 cells. Interestingly, we determined that a possible negative regulator of Cyr61 is present in MCF-7 cells. By contrast, the eects are dierent when Cyr61-overexpressing cells are treated with these agents. In addition, we demonstrated that both TPA and vitamin D upregulate the expression of Cyr61 in breast cancer cells that express high levels of ER, such as MCF-7 cells. In contrast, the dierentiating agent RA inhibits the expression of Cyr61 in MCF-7 cells. All of these results are consistent with our previous ®ndings that Cyr61 promotes breast cancer cells and tumor growth, and that tumor-promoting agents have a positive impact on cells in which Cyr61 expression is low, whereas these agents have no signi®cant eect on cells that express high levels of Cyr61. On the other hand, downregulation of the growth-promoting activity of Cyr61 by RA may account for the ability of RA to induce growth inhibition and apoptosis in breast cancer cells.
In conclusion, we demonstrate that regulation of Cyr61 is involved in breast cancer progression, and that Cyr61 should be considered as a new target for therapy. We have demonstrated that Cyr61 is highly expressed in breast carcinomas and that it induces the progression of breast cancer in vitro and in vivo. We are therefore currently investigating the mechanisms that account for Cyr61 induction of breast cancer progression.
